妇科恶性肿瘤患者ERBB2/HER2基因扩增的分子特征、临床意义与未来方向
基于AACR GENIE数据库(版本13.1)分析6961例妇科恶性肿瘤患者,ERBB2扩增总体发生率为3.8%,在卵巢黏液性癌(14.4%)、子宫浆液性癌(13.2%)、子宫透明细胞癌(9.4%)和子宫癌肉瘤(7.9%)中最高,TP53野生型子宫内膜样癌中罕见(0.4%)。
要点
- ERBB2扩增总体发生率3.8%,卵巢癌占49.1%、子宫内膜癌45.2%、宫颈癌5.7%。
- 卵巢黏液性癌(14.4%)、子宫浆液性癌(13.2%)、子宫透明细胞癌(9.4%)、子宫癌肉瘤(7.9%)ERBB2扩增发生率较高。
- TP53野生型子宫内膜样子宫内膜癌中ERBB2扩增罕见(0.4%)。
核心结论
- ERBB2扩增在子宫浆液性癌和卵巢黏液性癌中常见,在子宫透明细胞癌和子宫癌肉瘤中也有较高发生率;子宫内膜样子宫内膜癌中发生率低,尤其在无TP53突变时。
研究设计与样本
- 访问AACR GENIE数据库(版本13.1),识别子宫内膜癌、卵巢癌和宫颈癌患者,选取有拷贝数基因变异数据的患者进行分析。
- 按肿瘤部位和组织学分层评估ERBB2扩增发生率,并利用cBioPortal提供的OncoKB数据库数据判定致病性基因组变异。
主要发现
- 共纳入6961例符合标准患者:卵巢癌49.1%、子宫内膜癌45.2%、宫颈癌5.7%。
- ERBB2扩增总体发生率为3.8%。
- ERBB2扩增发生率最高见于卵巢黏液性癌(14.4%)、子宫浆液性癌(13.2%)、子宫透明细胞癌(9.4%)和子宫癌肉瘤(7.9%)。
- TP53野生型子宫内膜样子宫内膜癌中ERBB2扩增罕见(0.4%)。
- ERBB2扩增肿瘤中观察到PI3K通路基因突变高发。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Investigate the prevalence of ERBB2/HER2 gene amplification among patients with gynecologic malignancies. METHODS: The American Association of Cancer Research (AACR) Genomics Evidence of Neoplasia Information Exchange (GENIE) (version 13.1) database was accessed and patients with endometrial, ovarian, and cervical cancer were identified. Patients with available data on the presence of copy-number gene alterations were selected for further analysis. Incidence of ERBB2 amplification following stratification by tumor site and histology was evaluated. Data from the OncoKB database, as provided by cBioPortal, was utilized to determine presence of pathogenic genomic alterations. RESULTS: A total of 6961 patients who met the inclusion criteria were identified: 49.1% with ovarian cancer, 45.2% with endometrial cancer and 5.7% with cervical cancer respectively. Overall incidence of ERBB2 amplification was 3.8%. Highest incidence of ERBB2 amplification was observed among patients with mucinous ovarian (14.4%), uterine serous (13.2%), uterine clear cell (9.4%), and uterine carcinosarcoma (7.9%). ERBB2 amplification was rare among patients with TP53 wild-type endometrioid endometrial cancer (0.4%). High incidence of mutations in genes of the PI3K pathway was observed among patients with ERBB2 amplified tumors. CONCLUSION: ERBB2 amplification is frequently encountered among patients with uterine serous carcinoma, and mucinous ovarian carcinoma. In addition, a high incidence was also observed among those with uterine clear cell carcinoma, and uterine carcinosarcoma. For patients with endometrioid endometrial carcinoma, incidence of ERBB2 amplification is low, especially in the absence of TP53 mutations.
引用
- Nasioudis D, Gysler S, Latif N, et al. Molecular landscape of ERBB2/HER2 gene amplification among patients with gynecologic malignancies; clinical implications and future directions. Gynecol Oncol. 2023. PMID: 38029652. doi:10.1016/j.ygyno.2023.11.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。